Literature DB >> 27280587

Knockdown of placental growth factor (PLGF) mitigates hyperoxia-induced acute lung injury in neonatal rats: Suppressive effects on NFκB signaling pathway.

Liang Zhang1, Shuang Zhao2, Lijie Yuan3, Hongmin Wu4, Hong Jiang5, Gang Luo5, Shimeng Zhao4.   

Abstract

Although supplemental high-level oxygen treatment can promote the survival of premature infants, hyperoxia may adversely induce acute lung injury (ALI) in newborns. Our prior work illustrated that hyperoxic exposure could enhance the release of placental growth factor (PLGF) in the lungs of neonatal rats. We therefore postulated that PLGF contributed to hyperoxic ALI in newborns and evaluated the anti-PLGF treatment mediated by systematic delivery of lentivirus in hyperoxic ALI in this study. Lentivirus particles containing PLGF specific shRNA were injected into neonatal rats prior to hyperoxic exposure (90% oxygen for 72h) to inhibit PLGF expression. Hyperoxia induced oxidative damages in lung tissues as evidenced by the increased malondialdehyde and myeloperoxidase, and the decreased antioxidant superoxide dismutase. Also, hyperoxia caused excessive infiltration of inflammatory cells and overproduction of proinflammatory cytokines (tumor necrosis factor-α, interleukin-1β and interleukin-6) in rat lung tissue. These pathological alterations were partly reversed by PLGF shRNA delivery. The expression levels and activities of metalloproteinase (MMP)-2 and MMP9 were up-regulated in response to hyperoxia, whereas down-regulated when PLGF was inhibited. Moreover, PLGF shRNA inhibited nuclear factor kappa B (NFκB) signaling delivery in hyperoxic rat lungs. Additionally, exogenous PLGF-induced activation of MMPs in rat RLE-6TN alveolar epithelial cells was suppressed by NFκB inhibitor pyrrolidine dithiocarbamate. These results suggest that therapy targeting PLGF may be beneficial for infants with hyperoxic ALI.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ALI; Hyperoxia; Inflammation; NFκB signaling pathway; Oxidative stress damage; PLGF

Mesh:

Substances:

Year:  2016        PMID: 27280587     DOI: 10.1016/j.intimp.2016.05.028

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

1.  Acute cytotoxicity and increased vascular endothelial growth factor after in vitro nitrogen mustard vapor exposure.

Authors:  Matthew D McGraw; So-Young Kim; Carl W White; Livia A Veress
Journal:  Ann N Y Acad Sci       Date:  2020-05-14       Impact factor: 5.691

2.  Pathogenic CD8+ T Cells Cause Increased Levels of VEGF-A in Experimental Malaria-Associated Acute Respiratory Distress Syndrome, but Therapeutic VEGFR Inhibition Is Not Effective.

Authors:  Thao-Thy Pham; Melissa Verheijen; Leen Vandermosten; Katrien Deroost; Sofie Knoops; Kathleen Van den Eynde; Louis Boon; Chris J Janse; Ghislain Opdenakker; Philippe E Van den Steen
Journal:  Front Cell Infect Microbiol       Date:  2017-09-20       Impact factor: 5.293

3.  Placental growth factor gene silencing mitigates the epithelial‑to‑mesenchymal transition via the p38 MAPK pathway in rats with hyperoxia‑induced lung injury.

Authors:  Shuang Zhao; Gang Luo; Hongmin Wu; Liang Zhang
Journal:  Mol Med Rep       Date:  2019-10-30       Impact factor: 2.952

4.  Anti-placental growth factor antibody ameliorates hyperoxia-mediated impairment of lung development in neonatal rats.

Authors:  Zhiqun Zhang; Ying Zhong; Xiaoxia Li; Xianmei Huang; Lizhong Du
Journal:  Braz J Med Biol Res       Date:  2020-01-24       Impact factor: 2.590

5.  Prevention of Oxygen-Induced Inflammatory Lung Injury by Caffeine in Neonatal Rats.

Authors:  Stefanie Endesfelder; Evelyn Strauß; Ivo Bendix; Thomas Schmitz; Christoph Bührer
Journal:  Oxid Med Cell Longev       Date:  2020-08-07       Impact factor: 6.543

6.  Caffeine prevents hyperoxia-induced lung injury in neonatal mice through NLRP3 inflammasome and NF-κB pathway.

Authors:  Shangqin Chen; Qiuping Wu; Dingjuan Zhong; Changchong Li; Lizhong Du
Journal:  Respir Res       Date:  2020-06-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.